Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia.

ABSTRACT:

Background

Elevated parathyroid hormone (PTH) levels have been reported as a potential risk factor for cognitive impairment. Compared with the general population, older adults with end-stage renal disease (ESRD) who are frequently affected by secondary hyperparathyroidism (SHPT) are at increased risk of developing dementia. The main objective of our study was to evaluate if the risk of dementia in older (age ≥66 years) ESRD patients differed if they were treated for SHPT.

Methods

Using the United States Renal Data System and Medicare claims, we identified 189 433 older adults without a diagnosis of dementia, who initiated dialysis between 2006 and 2016. SHPT treatment was defined as the use of vitamin D analogs, phosphate binders, calcimimetics or parathyroidectomy. We quant

SUBMITTER: Mathur A 

PROVIDER: S-EPMC9585471 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature